Molecular Imaging and Fluorescence Endoscopy Leader DPM Secures Hundreds of Millions in Series B Funding Led by SoftBank China and Zhongguancun Longmen Investment

VCBeat (WeChat: vcbeat) learned at the earliest opportunity,Recently,DPM (including Beijing Digital Precision Medical Technology Co., Ltd. and Zhuhai Di Pu Medical Technology Co., Ltd., hereinafter referred to as “DPM”) announced the completion of its Series B financing, amounting to hundreds of millions of yuan. This round was co-led by SBCVC and Zhongguancun Longmen Investment, with participation from Hangzhou Risheng and Jiangsu Haoyue Fund. WinX Capital served as the exclusive financial advisor. The proceeds from this financing will further accelerate DPM’s product innovation, market expansion, and team building.

DPM CompanyIncubated at the Key Laboratory of Molecular Imaging of the Chinese Academy of Sciences, DPM Company achieved rapid growth after transforming scientific and technological achievements into commercial applications through the equity valuation of intellectual property. Leveraging the laboratory’s robust reserves of cutting-edge technologies, the company has independently developed and manufactured 4K fluorescence endoscopic camera systems, medical endoscope cold light sources, near-infrared fluorescence imaging systems, fluorescence molecular imagers, and white-light endoscopic camera systems. Furthermore, it has researched, developed, and planned a comprehensive portfolio of molecular imaging equipment and consumables, including fluorescent molecular imaging contrast agents and magnetic nanoparticle imaging diagnostic devices, establishing itself as an industry leader in the field of molecular imaging technology.

Driven by favorable policies and continuous product iteration and upgrades, domestic high-end endoscope manufacturers have entered a golden period of development to break the foreign monopoly. Shuzi Jingzhun has established a product matrix comprising three series of high-end optical molecular imaging surgical navigation systems—SuperEye, SmartEye, and WiseEye—as well as white-light endoscopic camera systems. Meanwhile, it is continuously enhancing its various product lines, including 3D endoscopes, 3D fluorescence endoscopes, and wide-spectrum AI-enabled endoscopes. CurrentlyThirteen products have obtained NMPA product registration certificates and concurrently received EU CE certification.

DPM's self-developed products have passed rigorousEvidence-based superiority clinical trials have demonstrated the product's efficacy and safety., obtained approvals from the National Medical Products Administration and the Beijing Municipal Medical Products AdministrationSpecial Approval for Innovative Medical Devices. In 2021, the Company took the lead in formulating industry technical standards, which were completed and released nationwide across ChinaTwo Group Standards。

DPM Company is the culmination of accumulated research from multiple major national projects. Previous research received support from key national special programs, including the National 973 Program, the Major Research Instrument Special Project of the National Natural Science Foundation of China, and the Nanotechnology Special Project of the Ministry of Science and Technology of China, andDPM Company led the National Key R&D Program on "Research and Development of Digital Diagnostic and Therapeutic Equipment" under the Ministry of Science and Technology., achieved a major breakthrough in precise intraoperative imaging for liver cancer. In terms of core technologies, it has wonU.S. Patent, over 100 intellectual property rights including PCT invention patents, national invention patents, and software copyrights. Related achievements have been honored with the Second Prize of the National Science and Technology Progress Award, the Second Prize of the National Technological Invention Award, the Gold Medal at the 43rd International Exhibition of Inventions Geneva, the Gold Medal at the 23rd China National Invention Exhibition, the First Prize in the China Medical Device Innovation and Entrepreneurship Competition, and recognition as one of the enterprises selected by the National Health Commission for the eighth batch of outstanding domestically produced endoscope products.

Precision medicine is a critical pathway for enhancing diagnostic and therapeutic standards and achieving personalized healthcare. Molecular imaging technology has been recognized as one of the ten most promising frontiers in medical science, with its emergence creating new opportunities for the advancement of precision medicine. Currently, DPM Company is strategically positioning itself in precision surgery through a comprehensive portfolio of molecular imaging equipment, while establishing a closed-loop “equipment plus consumables” ecosystem anchored by molecular imaging contrast agents. In the future, leveraging novel magnetic nanoparticle-based disease screening and imaging technology, DPM Company will expand from the realm of precision surgery into the broader domain of precision health.

Professor Tian Jie, Chairman of DPMStatement: We extend our sincere gratitude to all professional investment institutions for their support and trust in DPM. This serves as a strong endorsement of DPM’s deep commitment to molecular imaging technology. Molecular imaging is undoubtedly a highly promising technology driving the advancement of precision surgical diagnosis and treatment. DPM possesses a complete value chain, spanning from theoretical research and core technology development to clinical translation and industrial commercialization. The core technologies underlying its products have received support from major national initiatives, including the National Basic Research Program (973 Program), the Major Scientific Instrument and Equipment Development Project of the National Natural Science Foundation of China, and the National Key R&D Program for Nanotechnology under the Ministry of Science and Technology. We are confident that this Series B financing will enable DPM to take solid steps forward on its path to becoming a leader in the post-precision era.

Zhao Gang, Partner at SBCVCStatement: The precision and intelligence of surgical procedures represent a significant unmet need, for which fluorescence molecular imaging technology offers an excellent solution. As a pioneer and leader in domestic fluorescence molecular imaging technology, DPM possesses strong capabilities in technological innovation and product commercialization. Through close collaboration with top-tier medical and biological experts both in China and abroad, the company has accumulated decades of experience in interdisciplinary R&D integrating medicine and engineering, achieving multiple key systemic inventions. The founding team, represented by Professor Tian Jie from the Chinese Academy of Sciences, demonstrates a persistent commitment to technological innovation that has deeply impressed us. We believe that under the leadership of its founding team and with the joint support of existing and new shareholders, DPM will surely stand out in the field of precision surgical products and further expand into the broad market for integrated precision diagnosis and therapy in the future.

Fan Zhe, Partner at Zhongguancun Longmen InvestmentLongmen Investment stated: Supporting the rapid development of high-quality, technologically innovative enterprises in specialized sectors is our long-term strategy. DPM stands out as one of the most innovative companies in China’s surgical precision medicine field, boasting leading technical expertise and forward-looking R&D capabilities in optical molecular imaging surgical navigation, while its endoscopic products have achieved breakthrough clinical performance. We believe that under the leadership of Professor Tian Jie from the Chinese Academy of Sciences and the founding team, the company will continue to drive industry progress in innovative surgical precision diagnosis and treatment. Longmen remains committed to supporting leading enterprises in becoming industry pioneers, working alongside our portfolio companies to create sustained long-term value for society.

Wei Xingjie, Founder of Hangzhou Risheng FundDPM is a high-tech enterprise possessing China’s top-tier molecular imaging technology, with its technological achievements leading both domestically and internationally, and even surpassing global advancements in niche fields such as targeted molecular probes and magnetic nanoparticle imaging. Risheng Capital is committed to investing in technology-driven enterprises that can address urgent national needs and strong societal demands, while enabling Chinese technologies and products to achieve global strategic reach. It empowers portfolio companies to rapidly bring their products to market, facilitating import substitution.

Liu Yueling, Founder of Jiangsu Haoyue FundIt is indicated that precision diagnosis and treatment technologies represent the developmental trend in advancing medical technological innovation. Leveraging years of accumulated experience in integrating medicine and engineering, the founding team of DPM has developed molecular imaging technology with independent intellectual property rights that rivals top international standards. This technology stands as one of the most promising medical technologies for the future, providing robust support for the advancement of China’s precision medicine capabilities. Haoyue Capital focuses on hard-tech innovations in healthcare, concentrating on trends in innovative and disruptive medical device technologies, digital health, and new healthcare business models. With an international perspective and a long-term development outlook, Haoyue Capital supports the future growth of its investment portfolio.

Dr. Zou Guowen, Founding Partner of WinX CapitalIt is evident that fluorescent molecular imaging has fundamentally expanded the visual capabilities of physicians, representing a key competitive frontier for the future of endoscopy. With years of accumulated expertise in this field, DPM has achieved systematic innovations and maintains a significant technological lead. Its products deliver white-light imaging performance comparable to that of international giants, while their fluorescent imaging capabilities are unrivaled globally, earning endorsement from numerous leading medical experts serving as committee chairs. Notably, the company holds clear intellectual property rights and possesses the rare ability to sustain positive R&D momentum. Currently, its product portfolio is receiving successive regulatory approvals, with commercialization progressing favorably. We are confident that, with the support of powerful shareholders, the company will emerge as a leader in the post-precision medicine era.

SBCVC, established in 2000, is a leading venture capital and private equity fund management firm dedicated to investing in high-growth, high-tech enterprises across Greater China. It has successfully invested in a series of outstanding companies, including Alibaba, Taobao, Focus Media, GDS Holdings, BGI Genomics, Dian Diagnostics, and Edan Instruments. Currently, SBCVC manages multiple USD and RMB funds, with investment sectors spanning information technology, healthcare, clean technology, consumer retail, and advanced manufacturing, covering all stages from early-stage to growth-stage and late-stage investments.

Longmen Investment is a market-oriented investment management institution jointly established by renowned entrepreneurs, seasoned investors, and capital market experts. Zhongguancun Longmen Fund is the first fund managed by Longmen Investment, with its primary contributors including the National Social Security Fund, the Beijing Municipal Government, and the Haidian District Government. Longmen Investment regards facilitating the “critical leap” for outstanding enterprises as its mission, striving to become the preferred cooperation platform for industry-leading companies. Driven by both investment and empowerment, Longmen Investment will deeply integrate its comprehensive pre-investment, mid-investment, and post-investment service capabilities, promoting the development of China’s technological innovation through equity investments in technology enterprises.

WinX Capital is a leading investment bank in China’s healthcare sector. Five members of its founding team hold Ph.D.s in Global Finance from the PBC School of Finance at Tsinghua University, and its frontline team averages over 10 years of experience in management, investment, and M&A, with cumulative transaction values exceeding RMB 30 billion. Headquartered in Beijing and Shanghai, WinX Capital serves more than 3,000 active institutional investors and industrial groups. In 2020 and 2021, it was consecutively ranked among the “Top 5 Most Promising Emerging Investment Banks in China” by 36Kr (WISE2020/2021); listed as one of the “Top 4 Most Active Financial Advisors in Healthcare” by First Voice in 2021; and recognized as one of the “Top 4 Best Financial Advisory Firms in Healthcare” in 2020 and “Top 2 Best Financial Advisory Firms in Healthcare” in 2021 by Qiming Technology & New Voice Innovation Services.